{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-006498","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.002511+00:00","generated_at":"2026-06-27T04:47:39.787299+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Trevi's Haduvio meets Phase 2 CANAL primary endpoint; 52% placebo-adjusted cough reduction in IPF patients","bullets":["Interim analysis (N=26) showed 52% placebo-adjusted reduction in daytime cough frequency (p<0.0001); 100% probability of success.","Company stops further recruitment into CANAL trial based on strong and consistent interim data.","Haduvio well tolerated; no new safety signals; one unrelated SAE reported.","Full CANAL trial data expected early Q3 2022, with approximately 40 total subjects."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-006498","json":"https://secwatch.observer/filing/0001564590-22-006498.json","markdown":"https://secwatch.observer/filing/0001564590-22-006498.md","text":"https://secwatch.observer/filing/0001564590-22-006498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022006498/0001564590-22-006498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022006498/trvi-8k_20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:47:39.787299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}